Drug Profile
Natalizumab biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 03 Jul 2015 Research is ongoing in USA
- 18 Jun 2015 Natalizumab biosimilar - Harvest Moon Pharmaceuticals is available for licensing as of 18 Jun 2015. www.harvestmoonpharma.com